システマティックな分析により,CDKN2Aが肝細胞癌の予後生物マーカーであると確認された
Shilin He1, Yanling Zhang2, Junjie Xu1,3
1General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, Zhejiang, China.
Discover oncology
|August 30, 2025
まとめ
この研究では,CDKN2Aが肝細胞癌 (HCC) で過剰発現し,免疫微環境に影響を与え,患者の生存率を低下させることが判明しました. CDKN2Aは,HCCの潜在的な予後バイオマーカーです.
科学分野:
- 腫瘍学
- 分子生物学
- 免疫学
背景:
- 肝細胞癌 (HCC) は,世界的な主要な癌です. 銅のホメオスタシスの障害は肝機能に影響し,細胞死経路であるクプロプトーシスは銅の蓄積と関連しています.
- HCC発現におけるクプロプトーシス関連遺伝子 (CRG) の特定の役割は完全に理解されていません.
研究 の 目的:
- 肝細胞癌 (HCC) のクプロプトーシス関連遺伝子 (CRG) の発現と予後的意義を調査する.
- CRG,腫瘍の免疫マイクロ環境,およびHCCにおける患者のアウトカムとの関連を調べる.
主な方法:
- HCCと正常な組織における10のCRGの発現の体系的な評価
- 遺伝子オントロジー (GO),KEGG経路濃縮,GSEAを含むバイオインフォマティクス分析.
- 免疫浸透の評価,カプラン- メイヤー生存分析,そしてCDKN2Aに対するコックス回帰.
- 免疫組織化学 (IHC) によるCDKN2Aタンパク質発現の検証
主要な成果:
- CDKN2AはHCC組織で有意に過剰発現した.
- バイオインフォマティクス分析は,CDKN2AをDNA複製,臓器分裂,細胞サイクルチェックポイントと関連付けています.
- 高いCDKN2A発現は, dendritic細胞とTh2細胞の浸透の増加と相関しているが,CD8+T細胞とNK細胞の浸透は減少した.
- 高いCDKN2A発現は全生存期間を短くすることを予測し,独立した予後リスク因子として特定されました.
結論:
- CDKN2AはHCCで著しく過剰発現し,腫瘍の免疫微環境を調節する.
- CDKN2AはHCCの有望な独立した予後バイオマーカーとして機能します.
- 増加したCDKN2A発現は,HCC患者の生存率低下と関連しています.
関連する概念動画
02:15M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:39Positive Regulator Molecules
5.6K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.6K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.9K
01:21Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K